Immediate Impact
68 standout
Citing Papers
Radiotherapy toxicities: mechanisms, management, and future directions
2025 Standout
Lorlatinib Versus Crizotinib in Patients With Advanced ALK -Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study
2024 Standout
Works of L. Isa being referenced
A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of non-small-cell lung cancer. The DISTAL 01 study
2004
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| L. Isa | 344 | 240 | 64 | 68 | 18 | 474 | |
| Gemma Cramarossa | 292 | 198 | 143 | 13 | 19 | 513 | |
| Sanne ten Hoorn | 215 | 90 | 33 | 17 | 16 | 420 | |
| K. Beerblock | 399 | 130 | 75 | 11 | 22 | 522 | |
| David Cade | 277 | 197 | 207 | 7 | 30 | 535 | |
| Carlos Carracedo | 248 | 130 | 172 | 30 | 13 | 542 | |
| I. N. Olver | 240 | 107 | 169 | 9 | 17 | 498 | |
| Burton Needles | 325 | 102 | 150 | 10 | 17 | 532 | |
| Marybeth Singer | 417 | 50 | 230 | 18 | 12 | 495 | |
| G. Arcangeli | 141 | 131 | 185 | 17 | 21 | 486 | |
| Nitin Sukumar | 211 | 218 | 100 | 13 | 20 | 502 |
All Works
Loading papers...